Multicenter Study of Decitabine Administered Daily for 5 Days Every 4 Weeks to Adults With Myelodysplastic Syndromes: The Alternative Dosing for Outpatient Treatment (ADOPT) Trial
David P. Steensma(Harvard University), Hagop M. Kantarjian(The University of Texas MD Anderson Cancer Center), Rena Buckstein(Sunnybrook Health Science Centre), Maria R. Baer(University of Maryland, Baltimore), Guillermo Garcia‐Manero(The University of Texas MD Anderson Cancer Center), Lucy A. Godley(University of Chicago), Julie S. Larsen(Janssen (United States)), James L. Slack(Memorial Sloan Kettering Cancer Center), Michael Cullen(Leidos (United States)), Sujata Arora(Tesaro (United States)), Maher Albitar(Genomic Health (United States))
Cited by 316
Related Papers
Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN
|Blood|2022|3.1k
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
|Blood|2022|2.8k
Leukemic IDH1 and IDH2 Mutations Result in a Hypermethylation Phenotype, Disrupt TET2 Function, and Impair Hematopoietic Differentiation
|Cancer Cell|2010|2.7k
Durable Remissions with Ivosidenib in <i>IDH1</i> -Mutated Relapsed or Refractory AML
|New England Journal of Medicine|2018|1.4k